Martin Mackay - Charles River Independent Director
| CRL Stock | USD 201.30 5.53 2.82% |
Director
Dr. Martin W Mackay Ph.D. serves as Independent Director of the company. Dr. Mackay is cofounder and Chief Executive Officer of Rallybio, a privatelyheld earlystage biotechnology company incorporated in January 2018. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research Development at Alexion Pharmaceuticals, Inc. and from July 2010 to January 2013, Dr. Mackay served as the President of RD at AstraZeneca PLC where he led the research and development organization and had overall accountability for delivering new products from its pipeline. Dr. Mackay extensive experience leading research and development organizations at both global pharmaceutical and biotechnology companies provides us with a unique combination of expertise. Dr. Mackay was a director since July 2017. since 2021.
| Age | 65 |
| Tenure | 3 years |
| Professional Marks | Ph.D |
| Address | 251 Ballardvale Street, Wilmington, MA, United States, 01887 |
| Phone | 781 222 6000 |
| Web | https://www.criver.com |
Martin Mackay Latest Insider Activity
Tracking and analyzing the buying and selling activities of Martin Mackay against Charles River stock is an integral part of due diligence when investing in Charles River. Martin Mackay insider activity provides valuable insight into whether Charles River is net buyers or sellers over its current business cycle. Note, Charles River insiders must abide by specific rules, including filing SEC forms every time they buy or sell Charles River'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Martin MacKay over a year ago Acquisition by Martin MacKay of 214000 shares of Rallybio Corp subject to Rule 16b-3 |
Charles River Management Efficiency
The company has Return on Asset of 0.0487 % which means that on every $100 spent on assets, it made $0.0487 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1192 %, implying that it generated $0.1192 on every 100 dollars invested. Charles River's management efficiency ratios could be used to measure how well Charles River manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Charles River's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.06 this year, although the value of Return On Tangible Assets will most likely fall to 0.12. At this time, Charles River's Deferred Long Term Asset Charges is quite stable compared to the past year. Return On Assets is expected to rise to 0.06 this year, although the value of Other Assets will most likely fall to 1,092.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Elisha Finney | Mettler Toledo International | 59 | |
| Jeffrey Davis | Laboratory of | 57 | |
| John Connaughton | IQVIA Holdings | 54 | |
| Paul Clark | Agilent Technologies | 72 | |
| James Fasano | IQVIA Holdings | 50 | |
| Laurie Glimcher | Waters | 66 | |
| Linda Baddour | Waters | 62 | |
| Thomas Salice | Waters | 61 | |
| Richelle Parham | Laboratory of | 53 | |
| Francis deSouza | Illumina | 53 | |
| Sue Rataj | Agilent Technologies | 63 | |
| Gary Hendrickson | Waters | 64 | |
| Heidi Kunz | Agilent Technologies | 66 | |
| John Danhakl | IQVIA Holdings | 64 | |
| John Leonard | IQVIA Holdings | 62 | |
| JeanLuc Belingard | Laboratory of | 72 | |
| Peter Neupert | Laboratory of | 65 | |
| Michael Berendt | Waters | 71 | |
| Robert Williams | Laboratory of | 72 | |
| Ronald Rittenmeyer | IQVIA Holdings | 73 | |
| Caspar Tudor | Waters | N/A | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0487 |
Charles River Labora Leadership Team
Elected by the shareholders, the Charles River's board of directors comprises two types of representatives: Charles River inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Charles. The board's role is to monitor Charles River's management team and ensure that shareholders' interests are well served. Charles River's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Charles River's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph JD, Corporate Strategy | ||
| Robert Bertolini, Independent Director | ||
| Birgit Girshick, Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian | ||
| James Foster, Chairman of the Board, President, Chief Executive Officer | ||
| Joseph LaPlume, Corporate Executive Vice President - Corporate Development and Strategy | ||
| Mark Mintz, Corporate Officer | ||
| Michael Knell, Corporate Senior Vice President Chief Accounting Officer | ||
| George Milne, Lead Independent Director | ||
| George Llado, Independent Director | ||
| Nancy Andrews, Independent Director | ||
| Victoria Creamer, Corporate Senior Vice President Chief People Officer. | ||
| JeanPaul Mangeolle, Independent Director | ||
| Gina Mullane, Chief VP | ||
| Richard Wallman, Independent Director | ||
| Pr Frearson, Corporate Officer | ||
| David Smith, Chief Financial Officer, Corporate Executive Vice President | ||
| James JD, President CEO | ||
| Matthew Daniel, General VP | ||
| Martin Mackay, Independent Director | ||
| Virginia Wilson, Independent Director | ||
| Flavia Pease, Corporate Executive Vice President | ||
| Amy Cianciaruso, Corporate Officer | ||
| Matthew JD, General VP | ||
| Todd Spencer, Corporate Relations | ||
| Deborah Kochevar, Independent Director | ||
| William Barbo, Corporate Executive Vice President and Chief Commercial Officer | ||
| Stephen Chubb, Independent Director | ||
| Richard Reese, Independent Director | ||
| George Massaro, Independent Director |
Charles Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Charles River a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0487 | ||||
| Profit Margin | 0.10 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 12.56 B | ||||
| Shares Outstanding | 51.14 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 99.08 % | ||||
| Number Of Shares Shorted | 1.85 M | ||||
| Price To Earning | 33.74 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Charles River Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Charles River. If investors know Charles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Charles River listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.21) | Earnings Share 8.01 | Revenue Per Share 78.97 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0487 |
The market value of Charles River Labora is measured differently than its book value, which is the value of Charles that is recorded on the company's balance sheet. Investors also form their own opinion of Charles River's value that differs from its market value or its book value, called intrinsic value, which is Charles River's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Charles River's market value can be influenced by many factors that don't directly affect Charles River's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Charles River's value and its price as these two are different measures arrived at by different means. Investors typically determine if Charles River is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Charles River's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.